lunes, 27 de agosto de 2018

Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome. - PubMed - NCBI

Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome. - PubMed - NCBI



 2018 Jul 30;4(3):261-268. doi: 10.3233/BLC-180180.

Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome.

Abstract

BACKGROUND:

Lynch syndrome is an autosomal dominant disorder that predisposes individuals affected to certain malignancies. Colon and endometrial cancers are the malignancies most highly associated with Lynch syndrome. However, growing body of evidence links Lynch syndrome to urological cancers.

OBJECTIVE:

This review aims to clarify the type of urological malignancies that fall under the Lynch-associated cancer spectrum.

METHODS:

Using PRISMA guidelines, a systematic search between January 1990 to February 2018, was conducted using the MEDLINE database with the application of the following MESH terms: colorectal neoplasms, hereditary nonpolyposis; DNA mismatch repair; urologic neoplasms; kidney pelvis; ureteral neoplasms; urinary bladder; carcinoma, transitional cell; prostatic neoplasms; testicular neoplasms.

RESULTS:

Upper tract urothelial cancers are well established under the Lynch spectrum. Increasing evidence supports its association with prostate cancer. However, there is, inconclusive and limited evidence for an association with bladder and testicular cancer.

CONCLUSIONS:

The evidence underpinning certain urological malignancies associated with Lynch syndrome has expanded in recent years. Our review may assist in providing a summary of the current standing in literature. However, we recommend further investigations to better clarify associations, particularly with prostate, bladder and testicular cancer.

KEYWORDS:

-testicular neoplasms; Colorectal neoplasms; DNA mismatch repair; carcinoma; hereditary nonpolyposis; kidney pelvis; prostatic neoplasms; transitional cell; ureteral neoplasms; urinary bladder; urologic neoplasms

PMID:
 
30112437
 
PMCID:
 
PMC6087433
 
DOI:
 
10.3233/BLC-180180

No hay comentarios:

Publicar un comentario